BTK and B-cell chronic lymphocytic leukemia: While novel agents, including BTK (Bruton’s Tyrosine Kinase) inhibitor (ibrutinib, zanubrutinib) and BCL2 (B cell lymphoma 2) inhibitor (venetoclax), have greatly improved the survival of CLL patients.